Improving HIV infection management using antiretroviral plasma drug levels monitoring: A clinician's point of view

Current HIV Research

Volumn 2, Issue 4, 2004, Pages 309-321

  Clevenbergh, Philippe ^a   Mouly, Stéphane ^a   Sellier, Pierre ^a   Badsi, Esma ^a   Cervoni, Jeanine ^a   Vincent, Valérie ^a   Trout, Hervé ^a   Bergmann, Jean François ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Adherence; Antiretroviral therapy; Efficacy; Inhibitory; Plasma drugs levels; Quotient; Therapeutic drug monitoring; Toxicity

Indexed keywords

AMPRENAVIR; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; DIDANOSINE; EFAVIRENZ; INDINAVIR; INTERLEUKIN 2; LOPINAVIR; MACROLIDE; MEFLOQUINE; METHADONE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PROTEINASE INHIBITOR; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SILDENAFIL; TENOFOVIR; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; WARFARIN; XENOBIOTIC AGENT;

AREA UNDER THE CURVE; BLOOD TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; ENVIRONMENTAL FACTOR; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INDIVIDUALITY; INSOMNIA; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NEUROLOGIC DISEASE; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 4544296207     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570162043351129     Document Type: Review

References (109)

1. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. (2003). Drugs. 63: 741-753.
2. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Heather Watts D, Smith E, Jimé nez E, Mofenson L and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. (2004). Antimicrobial Agents and Chemotherapy. 48: 430-436.
3. Acosta EP, Gerber JG; Adult Pharmacology Committee of the AIDS Clinical Trials Group. (2002). AIDS Research and Human Retroviruses. 18: 825-834.
4. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. (1999). Pharmacotherapy. 19: 708-712.
5. Ahuja TS, O'brien WA. (2003). American Journal of Kidney Diseases. 41: 279-291.
6. Alcoba M, Cuevas MJ, Perez-Simon MR, Mostaza JL, Ortega L, Ortiz de Urbina J, Carro JA, Raya C, Abad M, Martin V; HAART Adherence Working Group for the Province of Leon, Spain. (2003). Journal of Acquired Immune Deficiency Syndrome. 33: 253-258.
7. Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, O'Shaughnessy MV, Harrigan PR. (2003). Journal of Infectious Diseases. 188: 541-548.
8. Back D, Blaschke T, Boucher C, Burger D, Fletcher C, Flexner C, Gerber J, Schapiro J. (2003). TDM guidelines. Available ar http://www.HIVpharmacology.com/
9. Back D, Gatti G, Fletcher C, Garraffo R, Huubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C,Perno CF. (2002). AIDS. 16: S5-37.
10. Baldwin CE, Sanders RW, Berkhout B. (2003). Current Medical Chemistry. 10: 1 633-642.
11. Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P, et al. (1992) Journal of Infectious Diseases. 165: 99-104.
12. Bani-Sadr F, Perre P, Peytavin G, Bernard L, Melchior JC, Perronne C, de Truchis P. (2001). Presse Medicale. 30: 731-735.
13. Bareggi SR, Cinque P, Mazzei M, D'Arminio A, Ruggieri A, Pirola R, Nicolin A, Lazzarin A. (1994). Journal of Clinical Pharmacology. 34: 782-786.
14. Barry M, Gibbons S, Back D, Mulcahy F. (1997). Clinical Pharmacokinetics. 32: 194-209.
15. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. (1999). Clinical Pharmacokinetics .36: 289-304.
16. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL; CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. (2002). AIDS. 16: 1131-1138.
17. Becker SL, Luber AD. (2002). Medscape General Medicine 4(2). At http://www.medscape.com (05/2004).
18. Bergshoeff AS, Fraaij PL, van Rossum AM, Wolfs TF, Geelen SP, de Groot R, Burger DM (2003). Antiviral Therapy. 8: 215-222.
19. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. (2003). AIDS Research and Human Retroviruses. 19: 825-835.
20. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, Ubolyam S, Stek M, Cooper D, Lange J, Phanupak P, Reiss P. (2003). Journal of Antimicrobial Chemotherapy. 51: 1231-1238.
21. Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J; ATHENA Cohort Study Group. (2003). AIDS. 17: 1157-1165.
22. Burger DM, Aarnoutse RE, Hugen PW. (2002). Current Opinion in Infectious Diseases.15: 17-22.
23. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA. (1998). Antiviral Therapy. 3: 215-220.
24. Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME, Lange JM; ATHENA Study Group. (2003). Therapeutic Drug Monitoring. 25: 73-80.
25. Campo RE, Moreno JN, Suarez G, Miller N, Kolber MA, Holder DJ, Shivaprakash M, De Angelis DM, Wright JL, Schleif WA, Emini EA, Condra JH. (2003). AIDS. 17: 1933-1939.
26. Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ. (2003). Journal of Clinical Pharmacology. 43: 133-140.
27. Casado JL, Moreno A, Sabido R, Marti-Belda P, Antela A, Dronda F, Perez-Elias MJ, Moreno S. (2000). HIV Clinical Trials. 1: 13-19.
28. Clevenbergh P, Garraffo R, Dellamonica P. (2003). HIV Clinical Trials. 4: 330-336.
29. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. (2002). AIDS. 16: 2311-2315.
30. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. (2003). Clinical Pharmacokinetics. 42: 223-282.
31. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, Beijnen JH. (2003). Therapeutic Drug Monitoring. 25: 367-373.
32. De Maat MM, Mathot RA, Veldkamp Al, Huitma AD, Mulder JW, Meenhorst PL, Van Gorp EC, Carlier H, Beijnen JH. (2002). Pharmacological Research.46: 295-300.
33. de Requena DG, Nunez M, Gallego O, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. (2002). HIV Clinical Trials. 3: 463-467.
34. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME. (2003). Clinical Pharmacokinetics. 42: 599-605.
35. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. (1998). Journal of Pharmaceutical Sciences. 87: 803-807.
36. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F. (2000). Journal of American Medical Association. 283: 205-211.
37. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P, Brinkman K. (2002). AIDS. 16: 737-745.
38. Dieleman JP, Sturkenboom MC, Jambroes M, Gyssens IC, Weverling GJ, ten Veen JH, Schrey G, Reiss P, Stricker BH; Athena Study Group. (2002). Archives of Internal Medicine. 162: 1493-1501.
39. Dumon C, Solas C, Thuret I, Chambost H, Lacarelle B, Michel G, Durand A. (2000). Therapeutic Drug Monitoring. 22: 402-408.
40. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P. (2000). AIDS.14: 1333-1339.
41. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. (1999). The Lancet, 353: 2195-2199.
42. Eagling VA, Back DJ, Barry MG. (1997). British Journal of Clinical Pharmacology. 44: 190-194.
43. Fichtenbaum CJ, Gerber JG. (2002). Clinical Pharmacokinetics. 41: 1195-1211.
44. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC. (2002). AIDS.16: 551-560.
45. Flexner CW. (2003). Topics in HIV Medicine. 11: 40-44.
46. Gallego L, Barreiro P, del Rio R, Gonzalez de Requena D, Rodriguez-Albarino A, Gonzalez-Lahoz J, Soriano V. (2004). Clinical Infectious Diseases. 38: 430-432.
47. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, Vella S, Bassetti D. (1999). AIDS. 13: 2083-2089.
48. Gatti G, Pontali E, Boni S, De Pascalis CR, Bassetti M, Bassetti D. (2002). HIV Medicine. 3: 125-128.
49. Gonzalez de Requena D, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. (2003). AIDS Patient Care and STDs. 17: 443-445.
50. Grub S, Delora P, Ludin E, Duff F, Fletcher CV, Brundage RC, Kline MW, Calles NR, Schwarzwald H, Jorga K. (2002). Clinical Pharmacology & Therapeutics. 71: 122-130.
51. Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A, Martin-Hidalgo A. (2003). Journal of AIDS. 33: 594-600.
52. Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, Wit FW, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH, Lange JM. (1998). AIDS. 2: F111-115.
53. Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. (1997). Pharmacy World and Science. 19: 159-174.
54. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. (2000). Proceedings of National Academic Sciences. 97: 3473-3478.
55. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E. (2003). Antimicrobial Agents and Chemotherapy. 47: 350-359.
56. Hugen PW, Burger DM, Aarnoutse RE, Baede PA, Nieuwkerk PT, Koopmans PP, Hekster YA. (2002). Therapeutic Drug Monitoring. 24: 579-587.
57. Hugen PW, Burger DM, Brinkman K, ter Hofstede HJ, Schuurman R, Koopmans PP, Hekster YA. (2000). Annals of Pharmacotherapy. 34: 465-470.
58. Ingelman-Sundberg M. (2004). Trends in Pharmacological Sciences. 25: 193-200.
59. Joly V, Yeni P. (2000). Annales de Médecine Interne (Paris). 151: 260-267.
60. Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. (2004). Clinical Infectious Diseases. 38: 426-429.
61. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM (1997). Antimicrobial Agents and Chemotherapy. 41: 654-660.
62. Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, Lopez-Colomes JL, Saballs P, Gimeno JL, Diez A. (2001). AIDS Patient Care and STDS.15: 193-199.
63. Kuper JI, D'Aprile M. (2000). Clinical Pharmacokinetics.39: 203-214.
64. Langmann P, Weissbrich B, Desch S, Vath T, Schirmer D, Zilly M, Klinker H. (2002). European Journal of Medical Research. 7: 309-314.
65. Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chene G, Preau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. (2003). Journal of Acquired Immune Deficiency Syndrome. 34: 497-499.
66. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, Leduc D, Perrin L, Hirschel B. (1997). AIDS.11: F95-99.
67. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. (2003). Antimicrobial Agents and Chemotherapy. 47: 594-600.
68. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. (2001). AIDS. 15: 71-75.
69. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. (1999). AIDS.13: 870-871.
70. McNicholl IR. (2004). Current Infectious Diseases Reports. 6: 159-162.
71. Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee SA, Nelson KE, Wu KC, Chen S, Tong W, Lai S. (2002). American Heart Journal. 144: 642-648.
72. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ. (1996). Nature Medicine. 2: 760-766.
73. Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Barcena R, Moreno S. (2004). Antiviral Therapy. 9: 133-138.
74. Mouly S, Paine MF, Watkins PB. (2004). Journal of Pharmacology and Experimental Therapeutics. 308: 941-948.
75. Mouly S, Paine MF. (2003). Pharmaceutical Research. 20: 1595-1599.
76. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. (1999). Journal of Infectious Diseases.179: 1116-1123.
77. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, Wu AW, Antinori A. (2000). Journal of Acquired Immune Deficiency Syndrome. 24: 123-128.
78. No Author. (2002). Aids Alert. 17: 18, 23, 13.
79. Nunez M, Gonzalez de Requena D, Gallego L, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. (2001). Journal of Acquired Immune Deficiency Syndrome. 28: 399-400.
80. Palella FJ , Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. (1998). New England Journal of Medicine. 338: 853-860.
81. Paterson DL, Potoski B, Capitano B. (2002). Journal of Acquired Immune Deficiency Syndrome. 31 Suppl 3: S103-106.
82. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. (2000). Annals of Internal Medicine. 133: 21-30.
83. Pecora Fulco P, Kirian MA. (2003). Annals of Pharmacotherapy. 37: 1325-1358.
84. Piscitelli SC, Gallicano KD. (2001). New England Journal Of Medicine. 344: 984-996.
85. Rainey PM. (2002). Therapeutic Drug Monitoring. 24: 26-31.
86. Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, Meneghetti G, Maserati R. (2003). AIDS.17: 2399-2400.
87. Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM. (1998). The Lancet. 352: 185-190.
88. Rendon AL, Nunez M, Gonzalez-Requena D, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. (2003). Journal of Acquired Immune Deficiency Syndrome. 34: 247.
89. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. (1996) . Annals of Internal Medicine. 124: 1039-1050.
90. Schmidt LE, Dalhoff K. (2002). Drugs. 62: 1481-502.
91. Simonsen JN, Fowke KR, MacDonald KS, Plummer FA. (1998). Current Opinion in Microbiology. 1: 423-429.
92. Singh BN. (1999). Clinical Pharmacokinetics. 37: 213 55.
93. Smith P. HIV ePharmacotherapy Network. (2001). Available at http://www.hiv.buffalo.edu/proteaseinhibitor.shtml
94. Solas C, Basso S, Poizot-Martin I, Ravaux I, Gallais H, Gastaut JA, Durand A, Lacarelle B. (2002). Journal of Acquired Immune Deficiency Syndrome, 29: 374-377.
95. Sperling RS, Roboz J, Dische R, Silides D, Holzman I, Jew E. (1992). American Journal of Perinatology. 9: 247-249.
96. Stein DS, Fish DG, Bilello JA. (1996). AIDS. 10: 485-492.
97. Taburet AM, Garraffo R, Goujard C, Peytavin G, Treluyer JM; in Prise en charge des personnes infectées par le VIH : recommandations du groupe d'experts. Rapport 2002, sous la direction du Professeur Delfraissy, Eds Flammarion.
98. Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chene G, Clavel F, Girard PM. (2004). Clinical Pharmacology & Therapeutics. 75: 310-323.
99. Torti C, Quiros-Roldan E, Regazzi-Bonora M, De Luca A, Lo Caputo S, Di Giambenedetto S, Patroni A, Villani P, Micheli V, Carosi G. (2004). Journal of AIDS. 35: 324-326.
100. Tran JQ, Gerber JG, Kerr BM (2001). Clinical Pharmacokinetics. 40: 207-226.
101. Urban AW, Bean P, Aziz D, Graziano FM, Neudeck BL. (2003). International Journal of Sexually Transmitted Diseases & AIDS. 14: 103-108.
102. Van Heeswijk RP. (2002). Therapeutic Drug Monitoring. 24(3): 323-331.
103. van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM (2002). Pediatric Infectious Diseases Journal. 21: 743-747.
104. Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF. (1997). Antimicrobial Agents and Chemotherapy. 41: 2433-2438.
105. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. (2001). AIDS. 15: 1089-1095.
106. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI. (1998). Journal of Clinical Pharmacology. 38: 106-111.
107. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. (1998). Journal of Pharmaceutical Sciences. 87: 1322-1329.
108. Watkins PB. (1997). Advanced Drug Delivery Reviews. 27: 161-170.
109. Young B, Fischl MA, Wilson HM, Finn TS, Jensen EH, DiNubile MJ, Zeldin RK. (2002). Journal of Acquired Immune Deficiency Syndrome. 31: 478-482.